Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 and zoledronic acid maintenance after autologous transplant in multiple myeloma
2013-001188-22Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Jun 2013
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin and zoledronic acid in multiple myeloma (MM), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoints: Clinical and laboratory progression of disease and Time to progression. Started Jun 2013; status: active.
02
Drugs
aldesleukinzoledronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-001188-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001188-22.